$1.82
+0.09 (+5.20%)
Open$1.81
Previous Close$1.73
Day High$1.95
Day Low$1.76
52W High$7.72
52W Low$5.61
Volume—
Avg Volume527.2K
Market Cap6.03M
P/E Ratio—
EPS$-1.87
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+336.8% upside
Current
$1.82
$1.82
Target
$7.95
$7.95
$5.82
$7.95 avg
$9.13
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 913.8K | 821.5K | 988.8K |
| Net Income | -134,164 | -149,522 | -162,197 |
| Profit Margin | -14.7% | -18.2% | -16.4% |
| EBITDA | -201,888 | -178,889 | -216,043 |
| Free Cash Flow | -124,461 | -98,758 | -111,181 |
| Rev Growth | +16.4% | +11.0% | +21.1% |
| Debt/Equity | 1.08 | 0.86 | 0.85 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |